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Abstract
Background:  Gonorrhoea, a bacterial infection caused by Neisseria gonorrhoeae, has been
increasing in several European countries, particularly among men who have sex with men (MSM)
and teenagers. We describe the epidemiology of gonorrhoea in Norway in the recent 15 years in
order to guide recommendations on the diagnosis, treatment and prevention of gonorrhoea. An
evaluation of the Norwegian Surveillance System for Communicable Diseases (MSIS) in 1994,
involving GPs and microbiological laboratories, suggested that the system has a high coverage,
capturing over 90% of patients diagnosed with gonorrhoea.
Methods:  Using MSIS data on gonorrhoea cases we analysed specific trends by route of
transmission, age, gender, anatomical sampling site, antimicrobial resistance and travel history from
1993–2007 and, to focus on more recent trends, from 2003–2007. MSM and heterosexual cases
were defined by route of transmission.
Results: From 1993 to 2007, 3601 gonorrhoea cases were reported. MSM cases increased from
10 in 1994 to 109 cases in 2004. From 2003–2007, the incidence of gonorrhoea was 5.4/100,000
person-years (95%CI: 4.9–6.0). Over these five years, MSM accounted for an average of 80 cases
per year, of which 69% were infected by casual partners. In the same period, 98% of heterosexually
infected had a positive swab from urethra only and only two (0.3%) from the pharynx. Only one
woman (0.5%) was positive from the rectum. From 1993 – 2007, antimicrobial resistance results
were reported for 3325 N. gonorrhoeae isolates (98% of cultured samples). The proportion
resistant to quinolone has risen from 3% in 1995 to 47% in 2007, with 81% of the latter isolated
from patients infected in Asia.
Conclusion: The overall incidence of gonorrhoea in Norway remains low, but the increasing
number of MSM cases calls for new, more effective approaches to prevention. Infections originating
from abroad represent a constant risk of importing antimicrobial resistant N. gonorrhoeae. Due to
the prevalence of quinolone resistant N. gonorrhoeae in Norway, third-generation cephalosporins
should replace quinolones as the first choice in treatment guidelines. We advocate antimicrobial
susceptibility testing for all cases and recommend taking samples for culture from all exposed
anatomical sites.
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Background
Gonorrhoea, a bacterial infection caused by Neisseria gon-
orrhoeae, is a highly communicable [1] sexually transmit-
ted infection (STI) and, due to a short incubation period,
may serve as an indicator of recent risky sexual behaviour
in symptomatic cases [2]. Since the seventies, when gon-
orrhoea was at its peak, the number of cases has decreased
dramatically in many European countries [3,4]. Neverthe-
less, this preventable and treatable infection has been
reported to be on the rise in several European countries
[3,5] since the late nineties, particularly among men who
have sex with men (MSM) [6-10] and teenagers [3,6,8].
Patients with gonorrhoea may experience symptoms such
as purulent discharge and dysuria. The majority of hetero-
sexual men (95% and more) are symptomatic, whereas up
to 60% of women may be asymptomatic carriers of the
disease for as long as 12 months [1]. Pharyngeal and rectal
infections, which are mostly asymptomatic [1], may be
important in gonorrhoeal transmission among MSM [11].
The risk of acquiring pharyngeal gonorrhoea by oral-gen-
ital heterosexual contact has been reported to be 14% for
men and 31% for women [12]. Clinical trials reported
pharyngeal gonorrhoea to be self-limiting within three
months [13,14]. Untreated genital gonorrhoea may lead
to serious late complications such as pelvic inflammatory
disease, fistula formation and urethral strictures [1]. Fur-
thermore, gonorrhoea increases susceptibility to HIV and
HIV shedding in HIV positive patients [15].
Since the mid seventies, when penicillinase producing N.
gonorrhoeae (PPNG) was first reported [1], treating gonor-
rhoea has presented an ongoing challenge around the
world. In a sentinel surveillance study from 2004, signifi-
cant proportions of N. gonorrhoeae isolates from 12 West-
ern European countries were resistant to azithromycin,
ciprofloxacin, penicillin or tetracycline and as much as
22% were resistant to more than one of these antimicro-
bials [16].
In Norway, under the Infectious Disease Control Act, all
clinicians and laboratories are legally obliged to notify
gonorrhoea cases to the Norwegian Institute of Public
Health (NIPH). Using data from the Norwegian Surveil-
lance System for Communicable Diseases (MSIS), we
describe the epidemiology of gonorrhoea in Norway in
the last 15 years (including specific trends by route of
transmission, age, gender, antimicrobial resistance, place
of infection and anatomical sampling sites) in order to
develop targeted recommendations for the diagnosis, pre-
vention and treatment of gonorrhoea [17].
Methods
Cases fulfilling any of the following criteria should be
reported to MSIS: 1. the patient has clinical symptoms
compatible with gonorrhoea and is epidemiologically
linked to another case; 2. N. gonorrhoeae was proven in the
patient's sample by culture, antigen testing or nucleic acid
amplification technique (NAAT) or 3. direct Gram-stained
smear for microscopy shows intracellular diplococci. The
case definition did not change during the study period. All
clinicians and all of the approximately 20 clinical micro-
biology laboratories in Norway report to the system [18].
The Norwegian population during the study period was
approximately 4.5 million.
Upon confirmation of a case of gonorrhoea, the labora-
tory sends a notification to the NIPH and a blank report-
ing form to the patient's clinician. The clinician fills the
form with additional clinical and epidemiological data
about the patient and sends it to the NIPH. All reports are
anonymous and linked with a unique non-identifying
number. NIPH uses laboratory reports to identify and
remind clinicians if they fail to report on a case. The sys-
tem achieves coverage of about 90% [18,19] and the data
is of high quality; missing variables are rare. Most of the
cases are initially reported by the laboratories; however, a
minority of cases is reported directly from two venereal
disease clinics and clinicians if direct microscopy of
Gram-stained smear is used for establishing the diagnosis.
Among the key data collected by the surveillance system
are: sex of the patient, date of sampling, month and year
of birth, country of residence, country of birth, country of
infection, reporting laboratory, type of diagnostic test
used, anatomical sampling site, susceptibility of N. gonor-
rhoeae to antimicrobials, reasons for testing, transmission
route and relation to the source person.
For the purpose of this study, we defined MSM cases as
men who acquired gonorrhoea infection from another
man (homosexual transmission). Similarly, we defined
heterosexual cases as persons who acquired gonorrhoea
infection from a partner of the opposite sex.
Reporting of PPNG was introduced in MSIS in 1993,
while reporting of quinolone resistance started in 1995.
No other resistance is currently reported in MSIS. Labora-
tories test all strains for penicillinase (betalactamase) pro-
duction and for susceptibility to the most relevant
antimicrobials, but the methods may vary by laboratory.
We analysed the data on all cases reported to MSIS from
1993 to 2007 by using Microsoft Excel and Stata 9.0. To
describe more recent trends, we analysed data over a five
year period from 2003 to 2007. We described cases
according to demographic characteristics and various risk
factors, including self-reported travel history and trans-
mission route. The annual incidence with a 95% confi-
dence interval (CI) was calculated using yearly population
estimates by Statistics Norway http://www.ssb.no. We
used Prais-Winsten autoregression to evaluate linearBMC Infectious Diseases 2009, 9:33 http://www.biomedcentral.com/1471-2334/9/33
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trends in all studied data over time, taking into account
autocorrelation.
Results
From 1993 to 2007 NIPH received 3601 reports of gonor-
rhoea cases diagnosed in Norway (Figure 1). The number
of diagnoses decreased from a high in 1993 of 346 cases
(8.0 per 100,000 population) to a low in 1998 of 166
cases (3.8 per 100,000 population). Cases peaked again in
2001 with 327 reports, of which 290 (89%) were diag-
nosed by culture and 35 (11%) by the newly available
NAAT. The mean incidence in the recent five-year period
(2003–2007) was 5.4 per 100,000 person-years (95% CI:
4.9–6.0). The sexual transmission route was reported for
3578 (99.4%) cases from 2003 to 2007 (Table 1).
Demographic data and groups by transmission route
In the years 2003 to 2007, among teenagers (10 to19
years) females represented the majority of heterosexually
transmitted cases (Table 1). Between 1993 and 2007, the
number of cases among all teenage cases did not increase
significantly (p = 0.100); however we did observe a con-
current increase among those aged 45 years and older in
all transmission groups (p = 0.001), from 13 cases in 1993
to 48 cases in 2007. The median age among heterosexu-
ally infected men and women has increased since the early
nineties (p < 0.001 for both), while the median age of
MSM has remained relatively stable at around 29 years (p
= 0.043) (Figure 2).
The majority of cases occurred in those born in Norway,
although cases among migrants and visitors from other
European countries and Asia are represented, especially
among heterosexuals (Table 1).
In the period from 1993 to 2007, 842 MSM were diag-
nosed with gonorrhoea; from a low of 10 (4% of all cases)
in 1994 to a high of 109 cases (41% of all cases) in 2004
(Figure 1). We observed a linear increase in the number of
cases (p < 0.001) in this group during the study period,
with an average of 80 cases per year since 2003. The
majority resided in Oslo city and acquired their infection
Number of gonorrhoea cases by major transmission routes in Norway (N = 3578), 1993–2007 Figure 1
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Table 1: Selected characteristics of sexually infected gonorrhoea cases reported to the Norwegian surveillance system for 
communicable diseases (N = 1257), 2003–2007.
Characteristic Selected categories Sexual transmission route
Heterosexual Homosexual Unspecified
Women
n = 185 (%)
Men
n = 645 (%)
Men
n = 405 (%)
Men
n = 22
Age Median age in years 27 34 31 41
10–19 years 32 (17) 25 (4) 20 (5) 0
20–24 years 42 (23) 80 (12) 64 (16) 1
25–34 years 59 (32) 216 (33) 160 (39) 5
35–44 years 33 (18) 188 (29) 110 (27) 7
≥ 45 years 19 (10) 136 (21) 51 (13) 9
Residence Oslo city 64 (35) 229 (35) 310 (76) 13
Other 121 (65) 416 (65) 95 (23) 9
Origin by birthplace Norwegian 131 (71) 505 (78) 350 (86) 21
European, other 16 (9) 51 (8) 32 (8) 0
Asian 23 (12) 60 (9) 8 (2) 0
African 6 (3) 22 (3) 5 (1) 1
Other 9 (5) 7 10 (2) 0
Reason for visiting Norway Temporary visit to Norway 15 (8) 19 (3) 13 (3) 0
First generation immigrant 16 (9) 65 (10) 22 (5) 1
Other, including permanent residents 154 (84) 561 (87) 370 (91) 21
Place of infection Infected abroad 55 (30) 364 (56) 62 (15) 2
- In Thailand 14 (8) 155 (24) 3 (7) 0
Infected in Norway 124 (67) 274 (43) 341 (84) 15
- In Oslo 47 (2) 145 (22) 294 (73) 13
Unknown 6 (3) 7 (1) 2 (0.5) 5
Source partner Steady partner 74 (40) 90 (14) 81 (20) 3
Casual partner 84 (45) 388 (60) 280 (69) 4
Prostitute 0 109 (17) 1 (0.2) 0
Other 8 (4) 14 (2) 19 (5) 0BMC Infectious Diseases 2009, 9:33 http://www.biomedcentral.com/1471-2334/9/33
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there (Table 1). In these five years, the proportion infected
by casual partners varied from 60 to 80%.
Since 1996, the ratio of heterosexual men to women,
infected with gonorrhoea in Norway, remained above 2
(Figure 3). Since 1993, symptoms were a reason for testing
in 61% of infected women compared to 93% in men. The
median duration of symptoms before sampling was four
days for men and eight days for women. Between 2003
and 2007, 40% of the women got infected by steady part-
ners compared to 14% of heterosexual men (Table 1).
Anatomical locations of positive samples
From 1993 to 2007, 2677 (75%) of all cases were positive
from a urethral swab. Of 91 patients diagnosed from a
pharyngeal swab, 70 (77%) were MSM, 13 were women
and eight were heterosexually infected men. Of 190 cases
diagnosed from a rectal swab, 171 (90%) were MSM and
19 were female; among the females four had samples pos-
itive both from rectal and endocervical swabs. The
number of positive rectal swabs in women has declined to
one or less per year since 2001. From 2003–2007, no het-
erosexually infected man had gonorrhoea confirmed from
more than one anatomical site (Table 2).
Antimicrobial resistance
From 1993 to 2007, 3399 cases (94%) were diagnosed by
culture. In 2001, culturing was used in 89% of the cases,
the lowest proportion in the entire period. Antimicrobial
resistance was reported for 3325 (98%) of all cultured N.
gonorrhoeae isolates. From 2003 to 2007, there has been a
marked increase in the number of isolates reported to be
quinolone resistant only, or both PPNG and quinolone
resistant (Figure 4). Quinolone resistance is mainly found
in isolates from patients infected in Asia. Among these
patients, the proportion of quinolone resistance rose from
8% in 1998 to 81% in 2007.
Imported gonorrhoea
In the early nineties, 70% of the cases reported acquiring
their infection in Norway. This proportion decreased to
around 60% in 2005 and 2006. Patients that reported
unsafe sex during a recent travel to a foreign country prior
to diagnosis, i.e. "imported gonorrhoea", were predomi-
nantly heterosexual men (80%). In 1993, 26% of the het-
erosexual infections among men were acquired outside
Norway, compared to 62% in 2007. From 2003 to 2007,
between 30 and 45 cases have been imported from Thai-
land to Norway every year. In 2003, 29% of all heterosex-
ual male cases had been infected in Thailand. Other cases
originated from around the world, with up to eight cases
per year per country acquired in Pakistan, the Philippines,
Brazil, Spain and Indonesia. Among those infected
abroad, travellers aged 45 years and older represented
21% and those in the age group 35–44 years represented
30% in the period from 2003 to 2007.
Discussion
The incidence of gonorrhoea in Norway from 2003 to
2007 (5.4 per 100,000 person-years) is similar to Sweden,
Unknown 18 (10) 44 (7) 24 (6) 15
Indications for testing Symptoms 114 (62) 631 (98) 331 (82) 20
Contact tracing 34 (18) 10 (1) 26 (6) 0
Own request 14 (8) 2 (0.3) 13 (3) 0
Blood donor 1 (0.5) 1 (0.2) 0 0
Pregnancy 1 (0.5) / / /
No specific reason 21 (11) 1 (0.2) 35 (8) 2
Diagnosed by General practitioner, private specialist 90 (49) 384 (59) 119 (29) 21
STI clinic 51 (28) 215 (33) 267 (66) 0
Hospital 24 (13) 13 (2) 5 (1) 0
Youth clinic 12 (6) 15 (2) 6 (1) 0
Other 8 (4) 18 (3) 8 (2) 1
Table 1: Selected characteristics of sexually infected gonorrhoea cases reported to the Norwegian surveillance system for 
communicable diseases (N = 1257), 2003–2007. (Continued)BMC Infectious Diseases 2009, 9:33 http://www.biomedcentral.com/1471-2334/9/33
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Finland and Denmark and much lower than in the UK
[20], making gonorrhoea a rare disease in Norway. How-
ever, several important challenges remain to be faced.
The majority of gonorrhoea cases are among heterosexual
men, but because we lack a population denominator to
calculate the incidence among MSM, it is not possible to
conduct a proper comparison among the transmission
groups. Nevertheless, we can conclude that MSM are cur-
rently the most vulnerable population to gonorrhoea
infection in Norway and that preventive measures against
STIs [21] among MSM are failing in Norway, similar to
observations in other countries [8-10,22,23]. The rising
trend of gonorrhoea among MSM is of particular concern
as the proportion of cases infected through a casual part-
ner is high, indicating increased risk for other STIs, includ-
ing HIV. The majority of MSM get infected with
gonorrhoea in the capital Oslo; therefore, preventive
measures should be particularly focused on this area.
Among heterosexual cases, the median age is increasing.
This may be due to the increasing age of the same risk group
over time or the fading effect of preventive programmes pri-
marily targeted at the young. Middle-aged men may be
more able and willing to afford sex tourism in the areas of
the world where gonorrhoea is still prevalent (see below).
Based on similar observations of an increasing trend in
reported gonorrhoea infections among people 45 years old
and older, the need for interventions, aimed specifically at
this group, has also been emphasised in the UK [24].
Median age of patients with gonorrhoea in Norway by major transmission routes (N = 3578), 1993–2007 Figure 2
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Among 21 European countries with diverse surveillance
systems, Norway had the eighth highest men to women
ratio of gonorrhoea cases in 2006 [20]. Among heterosex-
ually acquired domestic cases, the number of males diag-
nosed is 2 to 3 times greater than females, similar to
reports from other countries [6,9]. Reasons for this gender
disparity may include: behaviour differences (promiscu-
ity, visiting prostitutes, partner notification etc.), biologi-
cal differences in developing symptoms, duration of
infection and a pool of undiagnosed cases among asymp-
tomatic women. Since women are more susceptible to
infection [1] and frequently experience an asymptomatic
course of infection, the persistence of endemic gonor-
rhoea in Norway might be fostered by undiagnosed
women. The gender ratio implies that a more thorough
approach to contact tracing is warranted; however this is
limited by the frequency of infections in heterosexual
men associated with casual partners or prostitutes (Table
1), making partner notification difficult. Since symptoms
were stated as a reason for testing in only 60% of women,
we can conclude that asymptomatic cases are being diag-
nosed with gonorrhoea as well.
While gonorrhoea has become rare in Norway, it should
still be considered as a diagnostic option. When making
decisions for testing, clinicians should be aware that many
women in Norway, similar to reports from other countries
[9,25], acquire their infection from a steady partner, hav-
ing no obvious risk-factors for gonorrhoea in their medi-
cal history. Furthermore, belated diagnosis might lead to
severe health complications as we experienced in a recent
gonorrhoea outbreak in Norway in 2008 [26].
The number of samples tested with a negative result in
Norway is unknown. There is little evidence whether sam-
pling from several anatomic sites increases the diagnostic
sensitivity [27], but studies among MSM show that sam-
pling from the urethra only may lead to a significant pro-
portion (up to 40%) of missed cases [22,28,29].
Regardless of the exposure, rectal co-infection with cervical
Ratio of heterosexual men to heterosexual women, infected with gonorrhoea; domestic cases only (N = 1637), Norway,  1993–2007 Figure 3
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gonorrhoea has been reported in up to 30% of infected
women [1], therefore the low number of women who
recently tested positive from the rectum (Table 2) may sug-
gest that rectal samples from women are rarely taken. In a
study in France, a prevalence of 6% of pharyngeal gonor-
rhoea among heterosexual men with urethral gonorrhoea
has been reported from 1999 to 2001 [23]. To tackle the
possible undiagnosed reservoir of infection, it is important
that sampling is carried out according to the exposures
rather than the presence of symptoms; although some
patients might be reluctant to provide the details of their
exposure (see "Unspecified" group, Table 2).
Antimicrobial resistant N. gonorrhoeae is an increasing
problem in Norway, exacerbated by a large proportion of
imported infections from Asia. Following their importa-
tion into Norway and subsequent onward spread within
the population, infections originating abroad are not eas-
ily identifiable [26]. Recently reported travel is not a reli-
able tool to guide treatment choices. More than 40% of
infections in 2006 and 2007 were quionolone resistant,
regardless of whether they were acquired domestically or
abroad (Figure 4), which implies that third generation
cephalosporins should replace quinolones as the first
choice empirical treatment for gonorrhoeal infections in
the Norwegian treatment recommendations [30]; similar
to recent recommendations in other countries [31,32]. As
resistance to third generation cephalosporins is already
emerging [16], improved surveillance of N. gonorrhoeae
resistance, involving reporting resistance to any relevant
antimicrobial, using nationally standardized methods, is
necessary for the timely review and revision of national
treatment guidelines. This may help to ensure that the
most clinically effective empirical treatments, ideally
achieving a cure rate of over 95% [33], will be used in the
future. This is feasible in Norway due to the prevalent
practice of diagnosing gonorrhoea with culture and a high
coverage of reporting to MSIS.
Although travellers who got infected with gonorrhoea rep-
resent a diverse group, some studies identified demo-
graphic factors such as male sex, single status and age of
<20 years [34] as associated with a higher frequency of
casual sexual intercourse abroad, while others identified
Table 2: Anatomical sites of N. gonorrhoeae isolates, reported to the Norwegian surveillance system for communicable diseases (N = 
1257), 2003–2007.
N. gonorrhoea isolated from*: Sexual transmission route
Heterosexual Homosexual Unspecified
Women
n = 185 (%)
Men
n = 645 (%)
Men
n = 405 (%)
Men
n = 22
Urethra 8 (4) 631 (98) 276 (68) 22
Cervix 143 (79) / / 0
Rectum 0 0 68 (17) 0
Pharynx 7 (4) 2 (0.3) 20 (5) 0
Urethra, rectum and pharynx 1 (0.5) 0 4 (1) 0
Urethra and pharynx 0 0 7 (2) 0
Rectum and pharynx 0 0 8 (2) 0
Rectum and urethra 0 0 15 (4) 0
Cervix and pharynx 1 (0.5) / / 0
Cervix and urethra 19 (10) / / 0
Other, unspecified 3 (2) 4 (0.6) 1 (0.2) 0
Unknown 3 (2) 8 (1) 6 (1) 0
* the categories are mutually exclusiveBMC Infectious Diseases 2009, 9:33 http://www.biomedcentral.com/1471-2334/9/33
Page 9 of 11
(page number not for citation purposes)
middle-aged and married travellers [35] as high-risk
groups. It is therefore interesting to note that male travel-
lers, older than 45 years, represent a significant propor-
tion among our cases and that as much as half of the
infected travellers are older than 34 years.
Among all the infections acquired outside of Norway,
Thailand, a known sex tourism destination [34] remains
the most prominent country associated with the acquisi-
tion of gonorrhoea since the nineties [36], especially
among heterosexual men. A similar situation has been
described in Denmark and Sweden [6,9]. Due to the high
prevalence of HIV infection in Thailand, the rise of
imported gonorrhoea is a stark reminder of the high-risk
sexual behaviour of some Norwegian travellers. Asympto-
matic travellers who had casual sex abroad rarely present
at the doctor's office, therefore screening for STIs might
not be possible [34].
We identified some potential limitations and weaknesses
of our study. The evaluation of the STIs reporting coverage
to MSIS was done more than a decade ago. All behav-
ioural data in the system are self-reported. As the spectrum
of collected variables in Norway is rather broad, some
missing data were noted. We defined MSM and heterosex-
ual cases according to the reported route of transmission.
This definition provides no insight into the actual sexual
orientation, behaviour or sexual practices of the patients
and is only related to a single exposure, at which patients
got infected. Culturing of N. gonorrhoeae, a method most
frequently used for laboratory confirmation of gonor-
rhoea in Norway, has specificity of 99% and sensitivity of
60 to 70% [37], which might be further affected by trans-
port conditions. Therefore, a negative laboratory sample
does not exclude gonorrhoea. Patients with negative tests
should still be reported, providing they experience clinical
symptoms compatible with gonorrhoea and are epidemi-
ologically linked to another case. In this scenario, report-
ing should arise from the clinicians' initiative; however no
such cases were reported during the entire period from
1993 to 2007. This could indicate that a small proportion
of gonorrhoea infections in Norway remain unreported.
Proportion of PPNG and quinolone resistance of 3399 cultured isolates of N. gonorrhoeae Norway, 1993–2007 Figure 4
Proportion of PPNG and quinolone resistance of 3399 cultured isolates of N. gonorrhoeae Norway, 1993–2007. 
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Although clinicians are strongly encouraged to obtain a
sample for culturing, some may skip reporting of cases
diagnosed with direct microscopy. Nevertheless, we con-
sider MSIS a representative and reliable source of data on
gonorrhoea cases in Norway.
The observed peak incidence in heterosexual cases in
2001 was partially influenced by the decision of one lab-
oratory to screen samples collected for Chlamydia testing,
with NAAT for both Chlamydia and gonorrhoea. In 2001,
this laboratory reported 46 cases in total – much higher
than in the previous (4 cases) and the following year (17
cases). Using NAAT for screening in low prevalence popu-
lations has been associated with lower positive predictive
value [38] and some of the reported cases might have
been false positive. This laboratory continued to use
NAAT in the following years and reported it as the diag-
nostic method in 75% of cases. Nevertheless, the peak in
2001 remains prominent even after excluding the cases
diagnosed with NAAT, and is largely due to heterosexual
cases infected in Norway. No increase in HIV and syphilis
was observed in this group at the same time or a year later
[17].
Conclusion
The overall incidence of gonorrhoea in Norway is low.
Heterosexual transmission is fairly stable, while there is a
worrisome increase among MSM. Since most of the MSM
report getting infected in Norway (Oslo), prevention
efforts at local MSM venues should continue. Further
research is necessary to identify more effective prevention
measures and reasons for the resurgence of STIs among
MSM Europe-wide. Gonorrhoea is frequently brought to
Norway from abroad with a higher risk of imported cases
being resistant to antimicrobials. As the link to the foreign
country might be lost soon after the introduction to Nor-
way, the widespread practice of culturing which enables
antimicrobial susceptibility testing should be further
encouraged. There is a need for standardisation of
national laboratory methods for susceptibility testing and
for improving the surveillance of antimicrobial resistance
to enable rapid revision of treatment guidelines when nec-
essary. We recommend taking samples for culture of N.
gonorrhoeae from all exposed anatomical sites.
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